A common cellular response to broad splicing perturbations is characterized by metabolic transcript downregulation driven by the Mdm2–p53 axis

A common cellular response to broad splicing perturbations is characterized by metabolic transcript downregulation driven by the Mdm2–p53 axis

Bibliographic Details
Main Authors:	Jade E. Varineau, Eliezer Calo
Format:	Article
Language:	English
Published:	The Company of Biologists 2024-02-01
Series:	Disease Models & Mechanisms
Subjects:	craniofacial disorders splicing p53
Online Access:	http://dmm.biologists.org/content/17/2/dmm050356

Similar Items

A Common Cellular Response to Broad Splicing Perturbations
by: Varineau, Jade E.
Published: (2024)

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition
by: Erhan Aptullahoglu, et al.
Published: (2023-01-01)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
by: Zuzana Mrkvová, et al.
Published: (2019-06-01)

Zmat3 splices together p53-dependent tumor suppression
by: Kathryn T. Bieging-Rolett, et al.
Published: (2021-05-01)

Snrpb is required in murine neural crest cells for proper splicing and craniofacial morphogenesis
by: Sabrina Shameen Alam, et al.
Published: (2022-06-01)

Modularized Perturbation of Alternative Splicing Across Human Cancers
by: Yabing Du, et al.
Published: (2019-04-01)

Corrigendum: Modularized Perturbation of Alternative Splicing Across Human Cancers
by: Yabing Du, et al.
Published: (2019-10-01)

MDM2-C Functions as an E3 Ubiquitin Ligase
by: Kim JY, et al.
Published: (2020-08-01)

p53 and MDM2 protein expression in actinic cheilitis
by: Maria da Conceição Andrade de Freitas, et al.
Published: (2008-12-01)

How Driver Oncogenes Shape and Are Shaped by Alternative Splicing Mechanisms in Tumors
by: Weronika Wojtyś, et al.
Published: (2023-05-01)

The MDM2–p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells
by: Yurika Nakagawa-Saito, et al.
Published: (2024-04-01)

Evolution of the p53-MDM2 pathway
by: Emma Åberg, et al.
Published: (2017-08-01)

p53 and p63 Proteoforms Derived from Alternative Splicing Possess Differential Seroreactivity in Colorectal Cancer with Distinct Diagnostic Ability from the Canonical Proteins
by: Ana Montero-Calle, et al.
Published: (2023-03-01)

Targeting Post-Translational Regulation of p53 in Colorectal Cancer by Exploiting Vulnerabilities in the p53-MDM2 Axis
by: Chunwei W. Lai, et al.
Published: (2022-01-01)

MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters
by: Kester Mo Henningsen, et al.
Published: (2021-12-01)

The p53–Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans
by: Venkatesh, Byrappa, et al.
Published: (2016)

Controlling the Mdm2-Mdmx-p53 Circuit
by: David L. Waning, et al.
Published: (2010-05-01)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
by: Vera V. Grinkevich, et al.
Published: (2022-06-01)

The Antiproliferative and Proapoptotic Effects of Cucurbitacin B on BPH-1 Cells via the p53/MDM2 Axis
by: Ping Zhou, et al.
Published: (2023-12-01)

Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
by: Javier Octavio Mejía-Hernández, et al.
Published: (2022-08-01)

Molecular and Biochemical Techniques for Deciphering p53-MDM2 Regulatory Mechanisms
by: Konstantinos Karakostis, et al.
Published: (2020-12-01)

Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX
by: Yali Wang, et al.
Published: (2022-06-01)

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
by: Johanna Huun, et al.
Published: (2017-04-01)

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials
by: Haohao Zhu, et al.
Published: (2022-07-01)

Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS)
by: Vasileia Tsintari, et al.
Published: (2022-07-01)

Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer
by: Koji Kitamura, et al.
Published: (2021-04-01)

Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
by: Yujun Zhao, et al.
Published: (2013-07-01)

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death
by: Nayeong Koo, et al.
Published: (2022-04-01)

Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction
by: Anastasia Beloglazkina, et al.
Published: (2020-03-01)

SPLICE-q: a Python tool for genome-wide quantification of splicing efficiency
by: Verônica R. de Melo Costa, et al.
Published: (2021-07-01)

Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
by: Raymond S. Traweek, et al.
Published: (2022-11-01)

Dynamical analysis of a delayed p53 oscillator model with p53-Mdm2 positive feedback
by: Hongli Yang, et al.
Published: (2022-09-01)

Deciphering the plant splicing code: Experimental and computational approaches for predicting alternative splicing and splicing regulatory elements
by: Anireddy S.N. Reddy, et al.
Published: (2012-02-01)

Alternative Splicing Dynamics of the Hypothalamus–Pituitary–Ovary Axis During Pubertal Transition in Gilts
by: Xiangchun Pan, et al.
Published: (2021-04-01)

A Second Career for p53 as A Broad-Spectrum Antiviral?
by: Joe B. Harford
Published: (2023-12-01)

Accessing a New Dimension in TP53 Biology: Multiplex Long Amplicon Digital PCR to Specifically Detect and Quantitate Individual <i>TP53</i> Transcripts
by: Annette Lasham, et al.
Published: (2020-03-01)

An overview of RNA splicing and functioning of splicing factors in land plant chloroplasts
by: Xuemei Wang, et al.
Published: (2022-12-01)

SplicedFamAlign: CDS-to-gene spliced alignment and identification of transcript orthology groups
by: Safa Jammali, et al.
Published: (2019-03-01)

Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53
by: Xin Tian, et al.
Published: (2016-10-01)

Regulation of the MDM2‐p53 pathway by the ubiquitin ligase HERC2
by: Jesús García‐Cano, et al.
Published: (2020-01-01)